WDSOF1 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of the WDSOF1 protein, a lesser-known but intriguing protein that is believed to play a role in various cellular processes. WDSOF1 is thought to participate in regulatory pathways that involve protein-protein interactions, signal transduction, and potentially intracellular communication. The structure of the WDSOF1 protein may contain specific motifs or domains essential for these interactions, allowing it to influence cellular functions related to growth, differentiation, or response to environmental stimuli. By targeting and inhibiting WDSOF1, these compounds block the protein's ability to engage in these interactions, altering the cellular processes in which it is involved and disrupting the regulation of biochemical pathways dependent on WDSOF1 activity.
The molecular mechanism of WDSOF1 inhibitors typically involves binding to key domains of the protein, preventing it from interacting with other proteins or signaling molecules. This inhibition alters WDSOF1's ability to modulate its target pathways, leading to changes in the downstream signaling events and cellular responses. Researchers employ WDSOF1 inhibitors to explore the specific roles this protein plays in various biological systems, studying how its inhibition affects processes such as cell signaling, protein stability, or molecular communication. These inhibitors serve as important tools in deciphering the exact biological function of WDSOF1, providing insight into its contribution to maintaining cellular homeostasis and the intricate regulatory networks in which it operates. Through this approach, researchers can better understand the complex molecular interactions that define WDSOF1's role in the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
MLN4924 is an inhibitor of NEDD8-activating enzyme (NAE), indirectly inhibiting DCAF13 by disrupting the neddylation of CUL4, essential for DCAF13-mediated ubiquitination. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin interferes with several signaling pathways, indirectly influencing DCAF13 function by modulating proteasomal degradation and ubiquitination processes. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor that indirectly affects DCAF13 by inhibiting the degradation of proteins targeted by the CUL4-DDB1-DCAF13 complex. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib, another proteasome inhibitor, can impact DCAF13 activity by modulating the degradation of ubiquitinated proteins. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide affects the ubiquitin-proteasome system, potentially altering DCAF13-mediated protein ubiquitination. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $49.00 $367.00 $2030.00 | 18 | |
Lenalidomide, a thalidomide derivative, similarly influences the ubiquitin-proteasome system and may impact DCAF13 activity. | ||||||
Pomalidomide | 19171-19-8 | sc-364593 sc-364593A sc-364593B sc-364593C sc-364593D sc-364593E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $98.00 $140.00 $306.00 $459.00 $1224.00 $1958.00 | 1 | |
Pomalidomide, related to thalidomide and lenalidomide, may influence DCAF13 activity by affecting the ubiquitin-proteasome system. | ||||||
VER 155008 | 1134156-31-2 | sc-358808 sc-358808A | 10 mg 50 mg | $199.00 $825.00 | 9 | |
VX-11e, an ERK inhibitor, can indirectly affect DCAF13 by altering signaling pathways intersecting with DCAF13-related processes. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
AZD6244 inhibits the ERK pathway and may indirectly influence DCAF13's role in protein ubiquitination. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib, a kinase inhibitor with broad targets, potentially impacts pathways indirectly influencing DCAF13 activity. | ||||||